Other News To Note
BioCryst Pharmaceuticals Inc., of Research Triangle Park, N.C., reported that in response to recent events including the termination of its planned merger with San Francisco-based Presidio Pharmaceuticals Inc. and setbacks in their peramivir and BCX5191 programs, as well as the delay in their BCX4161 program, it is restructuring and implementing a focused strategy to advance its hereditary angioedema (HAE) and antiviral programs.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST